The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL		
OMB Number:	3235- 0076	
Estimated a burden	average	
hours per response:	4.00	

1. Issuer's Identity

	Previous	Nara	En titu Tura
CIK (Filer ID Nun	nder) Names	None	Entity Type
0001620463	M3 Biotech	nology, Inc.	X Corporation
Name of Issue	r		Limited Partnership
Athira Pharma, Inc.			Limited Liability Company
Jurisdiction of			General Partnership
Incorporation/Organ DELAWARE	lization		Business Trust
	tion/Organization		Other (Specify)
Year of Incorpora	uon/Organization		
X Over Five Years Ago	·(T 7)		
Within Last Five Years (S	pecify Year)		
Yet to Be Formed			
2. Principal Place of Busines	s and Contact Information		
Name	of Issuer		
Athira Pharma, Inc.			
	Address 1	Str	eet Address 2
4000 MASON ROAD, SUIT	TE 300	BOX 352141	
City	State/Province/Country	y ZIP/PostalCode	Phone Number of Issuer
SEATTLE	WASHINGTON	981952141	5095927191
3. Related Persons			
Last Name	Fir	rst Name	Middle Name
Kawas	Leen		
Street Address 1	Street	t Address 2	
4000 Mason Road, Suite 300	Box 352141		
City	State/Pro	ovince/Country	ZIP/PostalCode
Seattle	WASHINGTON	9819	952141
Relationship: X Executive 0	Officer X Director Promo	ter	
Clarification of Response (if	Necessary):		
Last Name	Fir	rst Name	Middle Name
Harding	Joseph	W.	
Street Address 1	Street	t Address 2	

Stre	et Address 1		Street Address 2	
4000 Mason Ro	oad, Suite 300	Box 352	2141	
	City	S	State/Province/Country	ZIP/PostalCode
Seattle		WASHI	INGTON	981952141
Relationship:	Executive Officer X	Director	Promoter	

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Fluke, Jr.	John	М.
Street Address 1	Street Address 2	
4000 Mason Road, Suite 300	Box 352141	
City	State/Province/Country	ZIP/PostalCode
Seattle	WASHINGTON	981952141
Relationship: Executive Office	r X Director Promoter	
Clarification of Response (if Neces	ssary):	
Last Name	First Name	Middle Name
Yamada	Tadataka	
Street Address 1	Street Address 2	
4000 Mason Road, Suite 300	Box 352141	
City	State/Province/Country	ZIP/PostalCode
Seattle	WASHINGTON	981952141
Relationship: Executive Officer	r X Director Promoter	
Clarification of Response (if Neces	ssary):	
Last Name	First Name	Middle Name
Litton	Mark	
Street Address 1	Street Address 2	

4000 Mason Road, Suite 300	Box 352141	
City	State/Province/Country	ZIP/PostalCode
Seattle	WASHINGTON	981952141
Relationship: X Executive Officer	Director Promoter	

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Moebius	Hansjoerg	
Street Address 1	Street Address 2	
4000 Mason Road, Suite 300	Box 352141	
City	State/Province/Country	ZIP/PostalCode
Seattle	WASHINGTON	981952141
Relationship: X Executive Officer	Director Promoter	

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Banking & Financia Commercial Bank Insurance Investing Investment Bankir Pooled Investmen	ing ng	Health Care X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care	Retailing Restaurants Technology Computers Telecommunications Other Technology
Is the issuer registered as an investment company under the Investment Company Act of 1940?		Manufacturing Real Estate Commercial	Travel Airlines & Airports Lodging & Conventions
Yes Other Banking &	No Financial Services	Construction REITS & Finance	Tourism & Travel Services Other Travel

Business ServicesResidentialOtherEnergyOther Real EstateImage: ConstructionImage: ConstructionEnergy ConservationEnvironmental ServicesImage: ConstructionImage: ConstructionOil & GasImage: ConstructionImage: ConstructionImage: ConstructionOther EnergyImage: ConstructionImage: ConstructionImage: ConstructionOil & CasImage: ConstructionImage: ConstructionImage: ConstructionOther EnergyImage: ConstructionImage: ConstructionImage: ConstructionOther EnergyImage: ConstructionImage: Construction</

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company	Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)(2)	Section 3(c)(10)	
	Section 3(c)(3)	Section 3(c)(11)	
Rule 504 (b)(1)(iii) X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)	
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)	
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		

7. Type of Filing

New Notice Date of First Sale 2018-12-17 First Sale Yet to Occur

X Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

Equity	Pooled Investment Fund Interests
X Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient	Recipient CRD Number X None	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X N	lone
Street Address 1	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply Check "All States" or check individual Sta	All States Horelon/non-LIS	
13. Offering and Sales Amounts		
Total Offering Amount \$4,650,000 US	D or Indefinite	
Total Amount Sold \$3,816,000 US	0	
Total Remaining to be Sold \$834,000 US	D or Indefinite	

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its

22

agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Athira Pharma, Inc.	/s/ Leen Kawas	Leen Kawas	Chief Executive Officer	2020-01-23

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.